Clinical Trial
Study Details
DISC-3405 is administered subcutaneously.
This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.
Study Overview
Contacts and Locations
University of Alabama at Birmingham
Birmingham, Alabama 35294
United States
University of California San Francisco (UCSF) Medical Center
San Francisco, California 94143
United States
Emory University
Atlanta, Georgia 30322
United States
Augusta University
Augusta, Georgia 30912
United States
University of Illinois Hospital and Health Sciences System
Chicago, Illinois 60612
United States
Innovative Hematology - Indiana Hemophilia & Thrombosis Center
Indianapolis, Indiana 46260
United States
Mount Sinai Hospital
New York, New York 10029
United States
Duke University Medical Center
Durham, North Carolina 27708
United States
Brody School of Medicine at East Carolina University
Greenville, North Carolina 27834
United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 45229
United States
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania 15213
United States